Mitsui & Co — 2018 Investments
1 investments dated 2018 · listed companies and verified rows first · show all
ArmaGenFeb 2018Acquired
ArmaGen develops blood-brain-barrier-crossing protein therapies for lysosomal storage disorders; acquired by JCR Pharmaceuticals in 2020.
BiotechCalabasas, US
Ruben Boado(Executive Officer)William Pardridge(Director)Mathias Schmidt(Executive Officer, Director)in
BoardJayson Punwani(Director)Martin Heidecker(Director)
Co-investorsMitsui Global InvestmentBoehringer Ingelheim Venture FundTakeda Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.